GENT, Belgium--(BUSINESS WIRE)--Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc.
Roche, a leader in research-focused healthcare, announced the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark. These new molecular ...
Treating an Underdiagnosed Disease Surveying the Current Treatment Landscape Emerging Drugs Options for Difficult-to-Treat Patients References Approximately 10% of this drug is excreted in the urine, ...
Please provide your email address to receive an email when new articles are posted on . Chronic HCV infection was associated with a 1.8-fold increased risk for pancreatic ductal adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results